rhamnazin has been researched along with Lung-Neoplasms* in 1 studies
1 other study(ies) available for rhamnazin and Lung-Neoplasms
| Article | Year |
|---|---|
Rhamnazin Enhanced Anti-Tumor Efficacy of Anti-PD-1 Therapy for Lung Cancer in Mice through Inhibition of PD-L1 Expression.
Emerging studies suggest the significance of broadening the benefit of anti-programmed cell death 1 (PD-1) therapy for lung cancer. The anti-angiogenic agents have been reported to alter the tumor microenvironment and contributes to efficiency of anti-PD-1 therapy. This study aims to investigate whether the anti-angiogenic agent rhamnazin enhances the efficacy of anti-PD-1 therapy in lung cancer. In Lewis lung carcinoma (LLC) xenografts, the combination of rhamnazin and anti-PD-1 treatment suppressed tumor growth, elevated the infiltration of CD4 Topics: Animals; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Granzymes; Humans; Interferon-gamma; Lung Neoplasms; Mice; Tumor Microenvironment; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A | 2023 |